MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer

Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer that rarely develops de novo in primary tumors and is commonly acquired during the development of treatment resistance. NEPC is characterized by gain of neuroendocrine markers and loss of androgen receptor (AR), making it r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Rep
Autors principals: Hsu, En-Chi, Shen, Michelle, Aslan, Merve, Liu, Shiqin, Kumar, Manoj, Garcia-Marques, Fernando, Nguyen, Holly M., Nolley, Rosalie, Pitteri, Sharon J., Corey, Eva, Brooks, James D., Stoyanova, Tanya
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8233352/
https://ncbi.nlm.nih.gov/pubmed/34172788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-92552-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars